First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans.

We describe a unique, complex case of a man resulted affected by both APS-2 and MEN-2a. The patient developed Hashimoto's thyroiditis, diabetes mellitus type 1 and AAD, despite testing negative for adrenal cortex autoantibodies (ACA) and steroid 21-hydroxylase autoantibodies (21-OHAb). Moreover, he had also a family history for MEN-2a and he first developed medullay thyroid cancer, then bilateral pheochromocytoma on the adrenal substrate of an AAD. On adrenal histology we found complete bilateral cortical atrophy in the presence of a lymphocytic infiltration and fibrosis, confirming an ACA and 21-OHAb-negative AAD. This datum is the first documented in a living individual and confirms that the absence of autoantibodies is not incompatible with an autoimmune dis‍ease and confirms that AAD is a cell-mediated autoimmune disease limited to the adrenal cortex and sparing medullary. In the light of a literature review concerning the association between APS and MEN, this is the first proven case to be reported in humans. Finally, our findings suggest that adrenal medullary tumor can develop even on an adrenal gland with cortical atrophy due to autoimmune adrenalitis. PMID: 32475862 [PubMed - as supplied by publisher]
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research

Related Links:

Source: Biological Rhythm Research - Category: Research Authors: Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Hyun Ji Son, Ha Yoon Mo, Nam Jin Yoo, Sug Hyung Lee
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 13 July 2020Source: Pathology - Research and PracticeAuthor(s): Jamal Halajzadeh, Parisa Maleki Dana, Zatollah Asemi, Mohammad Ali Mansournia, Bahman Yousefi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Publication date: Available online 12 July 2020Source: Pathology - Research and PracticeAuthor(s): Milena Vuletic, Snezana Jancic, Sanja Milenkovic, Marinko Paunovic, Biljana Milicic, Nina Jancic, Biljana Perunicic, Zivana Slovic
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Conclusion: Only one third reached dietary intake of folate, but deficiencies of folate and B12 were low. Psoriasis severity was negatively correlated with circulating folate and B12. Stopping smoking and a folate rich diet may be important targets for managing psoriasis.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
Conclusion: FN made in the 4:3:3 ratio of powder of corn, powder of bean cake defatted and powder of peeled whole potato is more effective to decrease the levels of postprandial 2h-blood glucose. FN is a staple type of functional food that could be used for the treatment of IGT.
Source: Current Nutrition and Food Science - Category: Nutrition Source Type: research
BOWEL cancer affects a person's digestive system in a number of ways. Tenesmus is one of the warning symptoms relating to digestion. The condition could signal early bowel cancer. What is tenesmus?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Could this technique help promote wound healing among oncology patients with complex wounds?Wounds
Source: Medscape Today Headlines - Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news
Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its investigational CD20xCD3 T-cell engaging bispecific mosunetuzumab has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior systemic therapies.“We are pleased that the FDA has granted Breakthrough Therapy Designation to mosunetuzumab, recognising the promising early efficacy data for this molecule and the remaining unmet need in follicular lymphoma,” said Levi Gar...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
             Basel, 14 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Blueprint Medicines Corporation (NASDAQ:BPMC), today announced the signing of a licensing and collaboration agreement providing exclusive rights to Roche for global co-development and commercialisation outside the United States (US), excluding Greater China*. In the US, Genentech, a member of the Roche Group, will obtain co-commercialisation rights to pralsetinib, Blueprint Medicine ’s investigational, once-daily oral precision therapy for the treatment of people with RET-altered ...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Addison's Disease | Autoimmune Disease | Cancer | Cancer & Oncology | Carcinoma | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | Hashimoto's Thyroiditis | Multiple Endocrine Neoplasia | Multiple Endocrine Neoplasia Syndrome | Pheochromocytoma | Thyroid | Thyroid Cancer | Thyroiditis